Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 9/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 6/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5735415 | 1.00 | PTGER4 (1.00) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6161926 | 0.86 | PTGER4 (1.00) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6161931 | 0.86 | PTGER4 (1.00) | PTGER4PTGER3PTGER2 | |
| SCHEMBL3680191 | 0.82 | PTGER4 (0.69) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5734360 | 0.82 | PTGER4 (0.69) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5734366 | 0.82 | PTGER4 (0.69) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5734355 | 0.82 | PTGER4 (0.69) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6160079 | 0.81 | PTGER4 (0.73) | PTGER4PTGER3PTGER2 | |
| SCHEMBL27601135 | 0.80 | PTGER4 (0.67) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5733262 | 0.79 | PTGER4 (1.00) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409455-B1 | PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | disclosed |
| US-6900336-B2 | 8-aza-11-deoxy prostaglandin analogues | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1409455-A1 | PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-21 | — | — | EP | disclosed |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | SYNTEX (U.S.A.) LLC | 2003-06-26 | — | — | US | disclosed |
| WO-2003008377-A1 | PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | PTGER4, FFAR4, PTGER1 | PTGER4 1/4885PTGER3 11/4885PTGER2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.